Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an injectable solution for intravenous use. It treats serious Gram‑positive bacterial infections such as MRSA, VRE, and various forms of pneumonia in adult patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic used to treat infections caused by resistant Gram‑positive bacteria.

Complicated skin and soft tissue infections: provides bacterial eradication and clinical cure in patients with MRSA‑related cellulitis. Community‑acquired bacterial pneumonia: improves outcomes by targeting Streptococcus pneumoniae and atypical pathogens. Nosocomial pneumonia: effective against hospital‑acquired Gram‑positive organisms, including multidrug‑resistant strains. Methicillin‑resistant Staphylococcus aureus (MRSA) infections: achieves rapid bacterial clearance in bloodstream and deep‑tissue infections. Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative mechanism of action for resistant enterococcal disease.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that usually resolve after therapy completion. - Headache: mild to moderate cranial discomfort during treatment. - Rash: skin erythema or pruritus without systemic involvement.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Peripheral neuropathy: sensory disturbances that may become irreversible. - Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperreflexia, and hyperthermia.

Before initiating Linezolid therapy, clinicians should consider several safety measures.

Monitor blood counts: regular CBCs to detect thrombocytopenia or anemia. Assess renal function: dose adjustment may be needed in severe impairment. Avoid serotonergic drugs: co‑administration can precipitate serotonin syndrome. Use with caution in hepatic impairment: liver disease may affect drug clearance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants): potential serotonin syndrome. - Sympathomimetic agents (pseudoephedrine, phenylephrine): may cause severe hypertension.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased bleeding risk. - Rifampin: induces metabolism, reducing linezolid plasma concentrations.